Approval · Notice of Compliance 19240 · 2017
POMALYST: Notice of Compliance 19240
Issued April 11, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19240
- Date
- April 11, 2017
- Company
- Celgene IncSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the product monograph with pharmacokinetic (pk) data of pomalidomide in patients with varying degree of renal or hepatic impairment, as well as the clinical impact of smoking on pomalidomide exposure
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| POMALYST | Not yet assigned | — |
Medicinal ingredients
- POMALIDOMIDE 1 MG per CAP
- POMALIDOMIDE 2 MG per CAP
- POMALIDOMIDE 3 MG per CAP
- POMALIDOMIDE 4 MG per CAP